{"classes":[{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG000","spread":"NA","value":"4.909"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG001","spread":"NA","value":"6.544"},{"groupId":"OG002","spread":"9.8","value":"5.873"},{"groupId":"OG003","spread":"12.5","value":"4.208"},{"groupId":"OG004","spread":"18.4","value":"6.028"},{"groupId":"OG005","spread":"24.2","value":"5.489"},{"groupId":"OG006","spread":"27.3","value":"5.038"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG007","spread":"10.0","value":"57.736"},{"groupId":"OG008","spread":"91.1","value":"48.001"},{"groupId":"OG009","spread":"28.0","value":"53.436"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG010","spread":"NA","value":"42.708"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"1"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG000","spread":"NA","value":"4.755"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG001","spread":"NA","value":"6.288"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG002","spread":"NA","value":"4.870"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG003","spread":"NA","value":"4.534"},{"groupId":"OG004","spread":"24.2","value":"6.072"},{"groupId":"OG005","spread":"22.0","value":"6.656"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG008","spread":"NA","value":"36.476"},{"comment":"Geometric coefficient of variation was not derived as only one participant was evaluated for this arm.","groupId":"OG009","spread":"NA","value":"53.085"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"1"},{"groupId":"OG010","value":"0"}],"units":"Participants"}],"title":"Cycle 3 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"}],"units":"Participants"}],"description":"The Vss of conjugated enapotamab vedotin for dose-escalation part is reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.3 mg/kg 1Q3W until the end of treatment.","id":"OG000","title":"Dose-escalation Part: Enapotamab Vedotin 0.3 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 1Q3W until the end of treatment.","id":"OG001","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 1Q3W until the end of treatment.","id":"OG002","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.5 mg/kg 1Q3W until the end of treatment.","id":"OG003","title":"Dose-escalation Part: Enapotamab Vedotin 1.5 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.0 mg/kg 1Q3W until the end of treatment.","id":"OG004","title":"Dose-escalation Part: Enapotamab Vedotin 2.0 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.2 mg/kg 1Q3W until the end of treatment.","id":"OG005","title":"Dose-escalation Part: Enapotamab Vedotin 2.2 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 2.4 mg/kg 1Q3W until the end of treatment.","id":"OG006","title":"Dose-escalation Part: Enapotamab Vedotin 2.4 mg/kg 1Q3W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.6 mg/kg 3Q4W until the end of treatment.","id":"OG007","title":"Dose-escalation Part: Enapotamab Vedotin 0.6 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 0.8 mg/kg 3Q4W until the end of treatment.","id":"OG008","title":"Dose-escalation Part: Enapotamab Vedotin 0.8 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.0 mg/kg 3Q4W until the end of treatment.","id":"OG009","title":"Dose-escalation Part: Enapotamab Vedotin 1.0 mg/kg 3Q4W"},{"description":"Participants with relapsed/refractory cancer (ovarian, cervical, endometrial, thyroid, NSCLC, or melanoma) received IV infusion of enapotamab vedotin 1.2 mg/kg 3Q4W until the end of treatment.","id":"OG010","title":"Dose-escalation Part: Enapotamab Vedotin 1.2 mg/kg 3Q4W"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants who were exposed to at least 1 dose of enapotamab vedotin and who had at least 1 postdose PK measurement. 'Number analyzed' denotes the number of participants evaluated for the specified time point.","reportingStatus":"POSTED","timeFrame":"For 1Q3W dosing regimen: Predose, EOI, and 2 and 5 hours after EOI on Day 1 of Cycles 1 and 3; For 3Q4W dosing regimen: Predose, EOI, and 2 and 5 hours after EOI on Day 15 of Cycles 1 and 3","title":"Volume of Distribution at Steady State (Vss) of Conjugated Enapotamab Vedotin for Dose-escalation Part","type":"SECONDARY","unitOfMeasure":"L/day"}